On October 5, the Federal Trade Commission Chairman sent letters to 24 major healthcare services companies warning about their price disclosures. The message included a pointed distinction: the CMS price-transparency rules, in the letters’ words, do not create a safe harbor from FTC Act liability.
A hospital can meet a specific disclosure requirement and still make a separate statement that misleads a patient about the cost of care. The question is what the patient reasonably understands the quoted price to include.
The FTC announcement signals attention to that question, especially for non-emergency services scheduled in advance. It does not announce a new rule or establish that any recipient violated the law.
CMS Already Requires Information Patients Can Use
The existing CMS framework has two principal disclosure components. Hospitals must publish a machine-readable file of standard charges and provide a consumer-friendly display of shoppable services. A qualifying price-estimator tool can satisfy the latter requirement.
The consumer display generally covers at least 300 services, combining 70 that CMS specifies with others the hospital selects, or as many as the hospital provides if fewer. It must use plain-language descriptions and group services with customary ancillary services.
The distinction is therefore not between a CMS requirement for raw data and an FTC expectation of understandable information. CMS already addresses consumer use. The FTC chairman is warning that compliance with those requirements does not resolve every question about a provider’s pricing communications.
A website can contain the required information while a separate advertisement, estimate, or scheduling conversation creates a different impression. Reviewing the website alone would miss that communication.
A Partial Price Can Look Like a Complete Price
The chairman’s letter identifies physician fees, facility fees, and portions of expected care as possible omissions. The concern arises when patients reasonably believe that a disclosed amount represents the total cost.
Consider a hypothetical advertisement offering a scheduled procedure for $2,000. An unavoidable professional fee is additional, but the offer does not make that clear. The amount might accurately describe the hospital’s own charge. It could still give the patient an inaccurate understanding of the purchase.
The useful review question is not simply whether $2,000 appears in the billing system. It is whether the offer communicates what that amount buys and what the patient will have to pay separately.
That requires attention to the words surrounding the price, the prominence of exclusions, and the stage at which those exclusions become apparent. A correction after the patient commits to care serves a different purpose from information available while alternatives remain practical.
Timing Matters as Well as Accuracy
The letter describes two theories. A material representation or omission can be deceptive if it is likely to mislead reasonable consumers. A practice can also be unfair if it causes substantial, not reasonably avoidable injury without outweighing benefits.
For scheduled services, the chairman connects late or incomplete information to lost opportunities to compare providers. His unfairness discussion expressly addresses information reasonably available in advance.
That qualification matters. Healthcare needs can change, and a reasonable estimate can differ from the final bill. The letter does not prescribe how to account for every uncertain clinical development, insurance adjustment, or independent clinician’s charge.
Those uncertainties do not answer a different question: was a known exclusion omitted from an amount presented as complete? A review should distinguish an unpredictable additional service from a foreseeable charge that the original communication concealed.
